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Summary Acute tumour lysis syndrome (ATLS) is a metabolic derangement (hyperuricaemia, hyperphosphataemia, hyperkalaemia and
hypocalcaemia) associated with lymphoproliferative malignancies. The nature and severity of the metabolic alterations are variable. Major
complications are oliguric acute renal failure and delays in initiating chemotherapy. Current management of ATLS includes hydration,
alkalinization, diuretics, when indicated, and the reduction of uric acid levels using allopurinol or urate oxidase. Allopurinol inhibits xanthine
oxidase, an enzyme that catalyses the conversion of hypoxanthine and xanthine to uric acid. Urate oxidase (Uricozyme®), a naturally
occurring proteolytic enzyme in many mammals, degrades uric acid to allantoins, which are ten times more soluble than uric acid and easily
eliminated by the kidneys. Recently, Sanofi Research isolated a recombinant urate oxidase (SR29142) as a cDNA clone from Aspergillus
flavus, expressed in the yeast strain Saccharomyces cerevisiae. Preclinical studies have documented its biological effects as a urolytic
enzyme. Twenty-eight healthy male volunteers received SR29142, and a rapid decline of uric acid below measurable levels was seen within
4 h in all patients receiving a dose of more than 0.10 mg kg-1. Currently, SR29142 is undergoing clinical studies in both Europe and the USA
in patients with acute leukaemias or B-cell non-Hodgkin's lymphoma to demonstrate its efficacy and safety in this population of patients at
highest risk of developing ATLS or its life-threatening sequelae.
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Acute tumour lysis syndrome (ATLS) is a metabolic derangement
associated with lymphoproliferative malignancies, which follows
chemotherapy-induced cell lysis and often occurs in patients with
high tumour burdens (Jones et al, 1995). It manifests mainly as
hyperuricaemia, hyperphosphataemia, hyperkalaemia and hypo-
calcaemia, leading to acute complications, such as oliguric renal
failure and delays in initiating chemotherapy. The nature and
severity of the metabolic alterations are variable, and are influ-
enced by the type of malignancy [mainly acute lymphocytic
leukaemia (ALL) with hyperleucocytosis and Burkitt's non-
Hodgkin's lymphoma], tumour load and growth fraction, timing
and intensity ofchemotherapy, as well as the magnitude ofthe cell
lysis and the patient's general condition with respect to hydration
and glomerular filtration rate.
Current management of ATLS is mainly by vigorous hydration
(3 1 m-2 day-'), alkalinization (30 mEq sodium bicarbonate 1-') to
maintain the urine pH at between 6.5 and 7, diuretics (mannitol or
furosemide) when indicated and the reduction ofuric acid levels. In
the USA, for example, this reduction is achieved using allopurinol
(commercially available as an oral formulation), whereas, in France
and Italy, urate oxidase (UricozymeO, Sanofi, France) is used.
ALLOPURINOL VS URATE OXIDASE
Allopurinol (4-hydroxypurinol), an analogue of xanthine, is
converted by xanthine oxidase to oxypurinol, which then binds
tightly to the xanthine oxidase, an enzyme that catalyses the
conversion of hypoxanthine and xanthine to uric acid. Because of
its tight binding to xanthine oxidase, oxypurinol blocks this
conversion. Allopurinol does not, however, degrade the uric acid
that is already present. Moreover, accumulated hypoxanthines and
xanthines may themselves precipitate in a manner similar to uric
acid in renal tubules, also leading to acute nephropathy and renal
failure (Band et al, 1970).
In contrast, urate oxidase (Uricozyme®), a naturally occurring
proteolytic enzyme in many mammals (although not in humans),
degrades uric acid to allantoins, which are ten times more soluble
than uric acid and easily eliminated by the kidneys. Side-effects are
few and are mainly allergic or anaphylactic reactions (Uricozyme®
data sheet, Sanofi, France). The agent is contraindicated in patients
with glucose-6-phosphate dehydrogenase to avoid intravascular
red cell haemolysis secondary to uricase oxidative action and the
production oflarge amounts ofhydrogen peroxide (which explains
its absence in humans), and also during pregnancy. Uricozyme® is
extracted, purified and lyophilized from industrial cultures of
Aspergillusfiavus, and has been commercially available in France
since 1974 and in Italy since 1984. It can be given intramuscularly
or intravenously at doses of 50-100 U kg-2 (Uricozyme® data
sheet, Sanofi, France).
The differences between allopurinol and UricozymeO are best
illustrated by the clinical outcome ofthe three largest international
studies in children with advanced stage B-cell non-Hodgkin's
lymphoma or ALL and, consequently, at the highest risk of
morbidity arising from ATLS (Patte et al, 1992; Pinkerton et al,
1993; Bowman et al, 1996). The three studies used very intensive
chemotherapy programmes. The British Children Cancer Study
Group (UKCCSG) protocols 9002 and 9003 adopted similar
induction and continuation chemotherapy to that of the French
Society of Pediatric Oncology (SFOP) LMB89. A 1-week, less
intensive, prephase induction was used in both protocols. The US
Pediatric Oncology Group (POG) protocol 8617 used early inten-
sive induction chemotherapy without the prephase induction week
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Figure 1 Comparison of plasma uric acid levels at diagnosis and during the
first 2 days of therapy with allopurinol or Uricozyme® (Pui et al, 1997)
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Figure 2 The decline in uric acid levels after a single injection of SR29142
used in both of the European studies. The UK and USA studies
used allopurinol, whereas the French study used Uricozyme®.
Only 1.7% (7 of410) ofpatients in the French study required renal
dialysis compared with 14.3% in the UK study and 23% (28 of
123) in the USA study.
Comparison of the magnitude and speed of action of
UricozymeO with allopurinol is depicted in Figure 1. One hundred
and twenty-six children with newly diagnosed ALL received
Uricozyme® during the first 5 days of induction therapy and were
compared with 129 similarly treated historical controls who had
received allopurinol to control leukaemia-associated hyperuric-
aemia (Pui et al, 1997). Patients treated with UricozymeO had a
rapid and greater decrease in their plasma uric acid, creatinine and
blood urea nitrogen levels.
SR291 42
Recently, Sanofi Research (Paris, France) isolated a recombinant
urate oxidase, SR29142, as a cDNA clone derived from
Aspergillusflavus and biosynthesized in the yeast Saccharomyces
cerevisiae. This tetrameric protein is made up of identical
subunits, each consisting of a single 301-amino-acid polypeptide
chain. Preclinical studies have documented its purity, potency and
biological effects as a uricolytic enzyme (Sanofi Research, unpub-
lished data).
A phase I, single-centre, open-label trial using a single dose of
SR29142, followed by repeated daily injections with dose level
escalation, was carried out in 28 healthy, male volunteers. For the
single intravenous dose, four volunteers at each dose level
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Figure 3 Median plasma uric acid levels of 20 patients enrolled in the
European study ACT 2511 in the dose validation phase
received either 0.05, 0.10, 0.15 or 0.20 mg kg-' of SR29142. The
second phase of the study had daily intravenous doses of 0.10,
0.15 and 0.20 mg kg-' for 5 consecutive days, four volunteers at
each dose level. The volunteers were subjected to clinical and
laboratory safety data, pharmacokinetic parameters and testing for
anti-SR29142 antibody. Figure 2 shows the rapid decline in uric
acid levels after a single injection. The response was also dose
related, and all patients treated with more than 0.10 mg kg-' had
levels below the limits of assay detection within 4 h.
Last year, two multicentre, open-label trials (European and
USA) using multiple daily injections of SR29142 were initiated
in patients with acute leukaemias or B-cell non-Hodgkin's
lymphoma. Each trial was designed with two phases. The first is
the dose validation stage with 14 patients to determine the effec-
tive dose of SR29142. The second is an accrual phase with at least
76 patients treated with the validated dose to confirm the efficacy
and safety ofthe SR29142.
SR29142 was given once daily for 5-7 days; supplemental
dosing was permitted every 12 h during the first 2 days in patients
with large tumour burdens. Chemotherapy was started 4-48 h after
the first dose of SR29142. Dose validation in both studies was
initiated at 0.15 mg kg-', with increments of0.05 mg kg-' per dose
level. No intrapatient dose escalation was allowed. Success was
defined as a uric acid level decrease, within 48 h of initiating
chemotherapy, to 6.5 mg dl-' or below in patients 13 years old or
younger, or to 7.5 mg/dl-' or below in patients older than 13 years
ofage. The validated dose was 0.15 mg kg-' in the European study
and 0.2 mg kg-' in the USA study. The accrual phases continued at
these doses. Figure 3 shows the uric acid levels of 20 patients
enrolled in the European study in the dose validation phase.
Within 4 h, patients had levels of uric acid that were undetectable
and remained low for at least 24 h after the last injection.
Preliminary results from 63 patients enrolled in the European
trial show a marked and rapid decline of uric acid levels in
62 patients after the first dose of SR29142 (G Leverger et al,
personal communication). Mean decreases in uric acid levels of
94%, 69% and 78% of pretreatment values were seen at 4, 24 and
48 h, respectively. Only three patients developed transient
moderate elevation of creatinine and blood urea nitrogen (BUN),
and no renal dialysis was required for any patient. One patient
developed a localized skin rash on the upper arm, and therapy was
discontinued after the second injection.
To date, 28 healthy volunteers and more than 260 patients have
received recombinant urate oxidase (SR29142) at doses ranging
from 0.05 to 0.2 mg kg-' day-'. Unlike allopurinol, SR29142
degrades uric acid, resulting in a rapid and steep decline to
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undetectable levels. SR29142 does not lead to substrate
accumulation of xanthines or hypoxanthines, which can cause
renal failure, and it has no effect on purine synthesis.
We conclude that SR29142 is a well-tolerated, fast-acting,
highly potent uricolytic agent that is effective in the prophylaxis
and treatment ofmalignancy-associated hyperuricaemia. SR29142
allows rapid initiation ofintensive chemotherapy in patients with a
large tumour burden who are at risk from acute tumour lysis or
renal failure.
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